timothy sykes logo

Stock News

Is It Too Late to Buy Establishment Labs Holdings Inc. Stock?

Timothy SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Establishment Labs Holdings Inc. is experiencing a significant boost, trading up by 17.87 percent on Friday. Key factors driving this surge include positive sentiment surrounding the announcement of robust quarterly earnings and enthusiasm over the launch of a new, innovative product line. With these announcements capturing investor attention, the company’s stock reflects strong market confidence.

Recent Key News for ESTA:

  • The company received FDA approval for its Motiva breast implants, a leap since 2013.
  • Following the approval, shares surged nearly 24% in after-hours trading.
  • Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants were approved for primary and revision augmentation.

Candlestick Chart

Live Update at 10:30:54 EST: On Friday, September 27, 2024 Establishment Labs Holdings Inc. stock [NASDAQ: ESTA] is trending up by 17.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of Establishment Labs Holdings Inc.’s Financials:

Let’s dive into Establishment Labs’ recent financials to get a grasp of its market positioning. In the past quarter, the company reported a revenue of $165.15M. That represents an impressive growth trajectory when you consider it from a span of five years. Revenue often drives investor sentiment, so a healthy increase can indicate positive market reception.

Profit margins offer a somewhat mixed bag, with a gross margin standing strong at 66% but an overall net profit margin hitting -54.97%. Without diving too deep into complex ratios, it’s clear the company is generating substantial revenue but high operating costs are eating into those profits. Revenue per share sits at $5.91, meaning each share generates a decent chunk of the total revenue.

On the balance sheet side, we’ve got a total asset line of $285.088M and total equity gross minority interest of $45.019M. A vibrant set of numbers indeed, but they should be taken with caution. A leverage ratio at 6.3 and total debt to equity at 4.37 signals a heavily leveraged company which could pose risks if not managed properly.

Debt can be a double-edged sword. It’s like borrowing a ladder to climb higher, but if you’re not careful, that ladder might just topple over. That’s how Establishment Labs is positioned; aggressive growth met with underlying financial risks.

Their quick ratio of 2.7 and current ratio of 4.4, however, shows they have a good amount of liquidity, essentially ready cash or near cash to cover short-term liabilities.

More Breaking News

Market Move Explanation:

The Impact of FDA Approval:

The FDA’s approval of Establishment Labs Holdings Inc.’s Motiva breast implants is monumental. When the FDA backs a product, it’s akin to a grand seal of approval, clearing hurdles that most companies stumble over. Shares of ESTA witnessed an electrifying 24% jump post-announcement, a testament to investor euphoria.

The approval of Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants, not just for primary but also for revisions, is a seismic development. Imagine the growth opportunities within the market of breast aesthetics, where safety and innovation dictate market share. The low complication rates in clinical trials have only helped cement confidence.

Balance and Profit Margins – Risks and Rewards:

On the surface, a gross margin of 66% portrays stellar efficiency, which draws a rosy picture for potential investors. However, digging deeper, the operating expenses paint a different story. With an EBITDA margin of -37% and a pre-tax profit margin of -41.9%, high costs have driven deep cuts into earnings.

Their operating income was negative, at -$9.344M, for the quarter ending 30 Jun 2024. Nonetheless, robust revenue and a growing market presence could turn these numbers, but it won’t be an overnight miracle.

Financial Health and Risk Assessment:

The company’s balance sheet shows a respectable total asset pool worth $285.088M. Yet, with a heavy debt load signaled by a total liabilities line of $240.069M and a current liabilities tally of $41.892M, it’s crucial for investors to recognize the potential headwinds. Their long-term debt stands at $196.721M, underlining the financial agility needed to navigate ongoing obligations.

Cash and equivalents are noted at $54.6M, ensuring they aren’t short of liquidity. However, aggressive debt management strategies will be imperative moving forward.

Insights from Stock Movement:

Intraday and multi-day stock data for ESTA highlight impressive climbs and volatile dips, encapsulating the market’s sentiments vividly. The stock opened at $49.61 on 27 Sep 2024 and oscillated within a high of $50 and a low of $46.2, closing at $48.555. High trading volume and a stark rise emphasize renewed investor interest post-FDA approval.

The five-minute candle data shows a flurry of activity around the stock’s pivotal move, reflecting investor excitement and market dynamics in real-time. Prices surged past $48.63, eventually touching a high of $50 before settling back at $48.555, illustrating the tussles between bullish and bearish sentiments.

Conclusion: Navigating Future Investment:

Investing in Establishment Labs at this juncture is like taking a calculated leap. The FDA approval acts as a booster rocket, but financial metrics require a seasoned pilot to navigate. High debt and negative profit margins caution against unbridled optimism, yet strong revenue growth and market potential present mouth-watering prospects.

Investors should keep an eye on how well the company manages its operational efficiencies and balances debt. Future earnings reports will be critical in assessing ongoing performance and sustainability.

For now, traders with a high-risk tolerance, who can navigate markets with agility, could find prospects within Establishment Labs alluring. Those looking for safer harbors might prefer to hold off until a steady profit trajectory is more apparent.

Curious about this stock and eager to learn more? Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success. Start your journey towards financial growth and trading mastery!

But wait, there’s more! Elevate your trading game with StocksToTrade, the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade harnesses the power of Artificial Intelligence to guide you through the market’s twists and turns. Discover insights on Robinhood penny stocks and top biotech picks to fuel your trading journey:

Ready to embark on your financial adventure? Click the links and let the journey unfold.

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Timothy Sykes

Tim Sykes is a penny stock trader and teacher who became a self-made millionaire by the age of 22 by trading $12,415 of bar mitzvah money. After becoming disenchanted with the hedge fund world, he established the Tim Sykes Trading Challenge to teach aspiring traders how to follow his trading strategies. He’s been featured in a variety of media outlets including CNN, Larry King, Steve Harvey, Forbes, Men’s Journal, and more. He’s also an active philanthropist and environmental activist, a co-founder of Karmagawa, and has donated millions of dollars to charity. Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”